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ABSTRACT
Introduction: Gastroenteritis is the leading cause of
morbidity and mortality among young children living in
resource-poor settings, majority of which is attributed
to rotavirus. Rotavirus vaccination can therefore have a
significant impact on infant mortality. However,
rotavirus vaccine efficacy in Sub-Saharan Africa and
Southeast Asia is significantly lower than in high-
income countries. Maternally derived antibodies, infant
gut microbiota and concomitant oral polio vaccination
have been proposed as potential reasons for poor
vaccine performance in low-income settings. The
overall aim of this study is to compare the role of
maternally derived antibodies and infant gut microbiota
in determining immune response to rotavirus vaccine
in high-income and low-income settings, using the
same vaccine and a similar study protocol.
Methods and analysis: The study is an
observational cohort in three countries—Malawi, India
and UK. Mothers will be enrolled in third trimester of
pregnancy and followed up, along with infants after
delivery, until the infant completes two doses of oral
rotavirus vaccine (along with routine immunisation).
The levels of prevaccination maternally derived
rotavirus-specific antibodies (IgG) will be correlated
with infant seroconversion and antibody titres, 4 weeks
after the second dose of rotavirus vaccine. Both within-
country and between-country comparisons of gut
microbiome will be carried out between children who
seroconvert and those who do not. The impact of oral
polio vaccine coadministration on rotavirus vaccine
response will be studied in Indian infants.
Ethics and dissemination: Ethical approvals have
been obtained from Integrated Research Application
System (IRAS, NHS ethics) in UK, College of Medicine
Research and Ethics Committee (COMREC) in Malawi
and Institutional Review Board (IRB), Christian Medical
College, Vellore in India. Participant recruitment and
follow-up is ongoing at all three sites. Analysis of data,
followed by publication of the results, is expected in
2018.
INTRODUCTION
This protocol followed published guidelines
for protocols for observational studies,
using Strengthening the Reporting of
Observational Studies in Epidemiology
(STROBE) checklist for cohort studies.1
Background
Gastroenteritis is the leading cause of mor-
bidity and mortality worldwide and is the
second commonest cause of death among
young children living in resource-poor set-
tings.2 The year 2013 witnessed over 558 000
deaths due to diarrhoea among children in
Strengths and limitations of this study
▪ This study will for the first time provide data
across populations on the impact of maternally
derived immunity and intestinal microbiota on
rotavirus vaccine take and immunogenicity in the
infant.
▪ This study will evaluate the performance of the
rotavirus vaccine in the routine schedule in two
developing countries where oral polio vaccine
will be soon phased out to be replaced with inac-
tivated polio vaccine as per the Global Polio
Eradication Initiative Strategic Plan for 2013–
2018.
▪ Limitations include different ages at immunisa-
tion between the UK (8 and 12 weeks of age)
and Malawi and India (6 and 10 weeks of age)
because of differences in national vaccination
schedules.
▪ Potential variations in breastfeeding practices are
also a limitation.
▪ Measurement outcomes may not correlate with
clinical outcomes (IgA may not be a correlate of
protection).
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the under-5 age bracket.3 Rotavirus (RV) is the predom-
inant aetiological agent of moderate-to-severe gastro-
enteritis in infants living in resource-poor settings.4
Diarrhoeal diseases attributed to RV constitute a major
proportion of illness and death among children
<5 years, especially in low-income countries.5 6 Oral vac-
cines provide an effective as well as a pragmatic
approach to alleviate the burden of enteric diseases for
which vaccines are available. RV vaccination has the
potential for signiﬁcant reductions in infant mortality
due to diarrhoea.7–9
Enteric vaccines must ideally elicit a robust local
immune response. While live attenuated vaccines such
as the oral polio vaccine (OPV) have had success in
eliminating the circulation of poliovirus from the major-
ity of countries, there is ample evidence that oral vac-
cines against poliomyelitis and cholera are less
immunogenic among children living in the low-income
countries, and therefore their effectiveness is compro-
mised in those populations which need them most.10 RV
vaccine efﬁcacy in Sub-Saharan African countries and in
Southeast Asia is signiﬁcantly lower than in high-income
countries.11–13 Maternally derived antibodies have been
proposed as one potential reason for poor RV vaccine
efﬁcacy in populations in low-income settings with high
exposure to RV.14 15 High titres of RV-speciﬁc secretory
IgA antibodies in breast milk inﬂuence the vaccine
strain immunogenicity even though withholding breast
feeding for a short duration does not inﬂuence the mea-
sured immune response to vaccines.16 Transplacental
transfer of malaria-speciﬁc IgG antibodies to the infant
is inﬂuenced by the maternal HIV status and a similar
phenomenon may be plausible for other antibodies in
countires.17 This is important because in countries
where the RV burden is high and early exposure to RV
is common, maternally derived immunity may be critical
in protecting newborn infants from RV disease prior to
immunisation. A low maternal exposure to RV in devel-
oped countries may result in lower levels of passive trans-
fer to the infant. Hence, the extent to which pre-existing
RV-speciﬁc IgG affects vaccine immunogenicity in
infants and their patterns in different countries need to
be studied.
The human gut microbiota has a role in controlling
metabolic and physiological functions like nutrient
usage, synthesis of vitamins, intestinal and immuno-
logical design, development and maturation.18–21
Gnotobiotic animal models provide insights into the
mechanisms by which the intestinal microbiota shape
the immune system and responses.22 Studies in Malawi
and Bangladesh have shown strong associations between
the gut microbiome composition and malnutrition.23 24
Intestinal microbiota will likely inﬂuence the immune
responses to vaccines. A role in inﬂuenza vaccination
has been recently reported.25 The gut microbiota has
been shown to inﬂuence enteric virus replication in
mice.26 Oral enteric live attenuated vaccines require rep-
lication in the intestinal tract and hence the gut
microbiota may directly and/or indirectly inﬂuence
vaccine strain replication, thus affecting the immune
response. Studies have also highlighted the role of
breast milk microbiota in shaping the infant gut micro-
biome composition thereby inﬂuencing immune system
maturation.27 28 Understanding the role of the micro-
biota in vaccine responses, in different populations, is
essential to understand what determines the ability of
vaccine strains to replicate in the gut and their interac-
tions with the local environment.
Rationale for the current study
This project will investigate the key maternal and infant
factors that may reduce RV vaccine performance in
infants living in resource-poor settings. RV is the leading
cause of severe gastroenteritis in infants worldwide where
the vaccine is not in routine use. Almost half a million
children die of RV gastroenteritis each year, mainly in
the developing world. Live, attenuated, orally adminis-
tered RV vaccines have the potential to greatly reduce
global diarrhoea deaths but for unexplained reasons
they work less well in the lowest income, highest disease
burden countries where they are needed most. Thus, in
Sub-Saharan Africa and Southeast Asia, vaccine efﬁcacy
against severe RV diarrhoea ranges between 43% and
66% compared with >90% in high-income countries.
Although levels of maternal immunity to RV are known
to be higher in mothers living in low-income countries,
their impact at the time of immunisation on RV vaccine
take and immunogenicity in the infant has not been
investigated. Also, the relationship between systemic anti-
bodies and secretory antibodies in breast milk is not
clear; although studies in which breast feeding has been
withheld immediately prior to RV immunisation have not
had any signiﬁcant impact on the vaccine immunogen-
icity. However, these studies do not rule out the interfer-
ence of breast milk antibodies on vaccine take.
Despite efforts to study the interface between com-
mensal bacteria and host immune responses, the role of
the intestinal microbiota on vaccine efﬁcacy remains
underinvestigated, and the impact of the composition of
microbial communities in the gut on live oral vaccine
efﬁcacy has not been elucidated to date. All of these
underline the fact that this study will yield information
that is required to understand the performance of RV
vaccines in developing countries and thus develop strat-
egies to improve them.
Aim and objectives
The overall aim of this study is to investigate the role of
maternally derived antibodies and the infant gut micro-
biome in determining the IgA immune response to RV
vaccine in high-income and low-income countries by
comparison of three populations using the same vaccine
and a similar study protocol (ﬁgure 1).
Objective 1: To investigate the role of maternally
derived antibodies in determining RV vaccine take and
immunogenicity in infants.
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Primary objective
To correlate levels of prevaccination maternally derived
RV-speciﬁc antibodies (IgG) with infant seroconversion
and antibody titres (immunogenicity) 4 weeks after two
doses of Rotarix administered at 6/8 and 10/12 weeks of
age. In addition, RV vaccine shedding will be assessed in
stool at day 7 after each vaccine dose as a proxy for
vaccine take.
Secondary objectives
▸ To evaluate the frequency and impact of early expos-
ure to RV infection prior to vaccination on RV
vaccine take and immunogenicity.
▸ To correlate RV-speciﬁc IgA in breast milk with infant
response to vaccine and levels of maternal serum IgG
and IgA with breast milk IgA.
Objective 2: To investigate if dysbiosis at the time of vac-
cination is associated with poor RV vaccine take and low
immunogenicity.
Primary objective
To compare gut microbial communities among infants
who seroconvert with those who do not, to determine
whether infants who fail to seroconvert following RV vac-
cination have a distinct microbiota.
Secondary objectives
▸ Role of dysbiosis in intestinal inﬂammatory disease:
To determine whether infants with biomarkers indica-
tive of intestinal inﬂammation, as measured by faecal
α-1 antitrypsin (AAT), and myeloperoxidase (MPO)
levels, and of systemic inﬂammation, measured by
levels of acid glycoprotein in blood, are associated
with an altered intestinal microbiota.
▸ To study the role of maternal microbiota imprinting
on the development of infant dysbiosis by studying
how the gut microbiota of each infant is determined
by the maternal gut and breast milk microbiota and
how it evolves from shortly after birth to the time of
vaccination.
Objective 3: To investigate the role of concomitant admin-
istration of OPV in RV vaccine take and
immunogenicity.
The impact of OPV coadministration on RV vaccine
response will be investigated in India by including an
additional arm where OPV will be replaced by inacti-
vated polio vaccine (IPV) at weeks 6 and 10 (following
OPV at birth). This will allow comparisons in children
with coadministered OPV and IPV. This will provide
crucial data that may enable prediction of the perform-
ance of RV vaccines when countries switch over from
OPV to IPV.
METHODS AND ANALYSIS
Study design and setting
The study is an observational cohort at all the three
sites. The study will recruit pregnant women in their
third trimester and subsequently their newborn infants
(mother–infant pairs) from the Zingwangwa Health
Centre in Blantyre, Malawi; the Chinnallapuram
Community Clinic in Vellore, India, and the Liverpool
Women’s Hospital in Liverpool, UK.
Figure 1 Conceptual framework
of the rotavirus vaccine
immunogenicity study.
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Inclusion criteria
▸ pregnant women consenting to participate in the
study;
▸ women willing to stay in the study area for 4 months
following delivery.
Exclusion criteria
▸ congenital immune deﬁciency;
▸ chronic renal or liver failure;
▸ other chronic illnesses which may affect the immune
response;
▸ mothers with non-singleton pregnancy;
▸ infant born with low birth weight/preterm
(<34 weeks gestation), congenital anomalies and
other neonatal complications requiring prolonged
hospitalisation.
Malawi study site description
Blantyre is (15.45°N 35.00°E) located in the southern
region of Malawi and is the second largest city in the
country.29 In 2008, the crude birth rate in Blantyre was
33.5 per 1000, with a fertility rate of 5.4 per woman, and
infant (<1 year of age) and child (1–4 years of age) mor-
tality rates being 98 and 55 per 1000 live births, respect-
ively, and a fertility rate of 5.30 The city is served by 11
health centres and one tertiary referral government hos-
pital, The Queen Elizabeth Central Hospital that pro-
vides free healthcare to the population. Recruitment for
the study will take place at the Zingwangwa Health
Centre, located in the Zingwangwa urban slum. The
health centre will provide antenatal and delivery ser-
vices, primary care, HIV and immunisation clinic ser-
vices and vaccination by research clinician in liaison with
the government nursing and midwifery staff. The com-
munity follow-up of the mother–infant pairs will be
done by study ﬁeld workers.
Vellore study site description
Vellore (12.92°N 79.13°E) is a town in Tamil Nadu, the
southernmost state of India. The site will enrol mother–
infant pairs from the areas of Ramnaickapalayam,
Chinnallapuram, Kaspa, Vasanthapuram and Vellore old
town. Ramnaickapalayam, Chinnallapuram, Kaspa and
Vasanthapuram are semiurban slums situated in the
western outskirts of Vellore with a population of about
49 000 and a birth rate of 17.5 per 1000 whereas Vellore
old town is an urban slum with a population of 22 000
and a birth rate14.6 of per 1000 population. ‘Beedi-work’
(indigenous cigarette made of unprocessed tobacco,
manually wrapped in ‘tendu’—Diospyros melanoxylon leaf)
is the predominant occupation, followed by unskilled
labour. The majority of the population is dependent on
income through daily wage-based jobs. Government
urban health centres in the area provide free healthcare
to the residents within the study area, and a government
teaching hospital is located ∼5 km away. The Christian
Medical College (CMC), Vellore, a not-for-proﬁt organ-
isation and its two outreach units—the Community
Health and Development (CHAD) and the Low
Cost-effective Care Unit (LCECU)—are located within a
few kilometres of the study area. As per the sample regis-
tration survey conducted by the Government of India,
the birth and infant mortality rates for urban Tamil
Nadu for the year 2013 are 15.8 live births per 1000
population and 22 deaths per 1000 live births, respect-
ively.31 A service clinic (the Chinnallapuram Community
Clinic) provides basic healthcare to all children under
the age of 5 years. Those children requiring hospitalisa-
tion or specialised care are referred to the secondary
(CHAD) or tertiary care hospital (CMC), as deemed
necessary by the attending physicians. The study will be
conducted in the research wing of the clinic. Trained
ﬁeld staff and study nurses who have established
a rapport with the community will be involved in
enrolment, immunisation and follow-up of the mother–
infant pairs.
Liverpool study site description
Liverpool is a city situated in the North West of England,
with an estimated population of 478 600 inhabitants.
Infant mortality rate in the city, 25 recorded in 2013, is
above regional and national levels, but is not statistically
signiﬁcant. Fertility rates in Liverpool are below national
levels. The percentage of women in Liverpool initiating
breast feeding within the ﬁrst 48 hours of birth was
53.2% in 2013–2014, the lowest among the main English
cities, and signiﬁcantly below the regional and national
levels. Immunisation coverage was 94.5% in 2013–
2014.32
Participants will be recruited at the Liverpool
Women’s Hospital (LWH). The LWH provides free
maternity services for the Liverpool city region encom-
passing the local authority districts of Halton, Knowsley,
Liverpool, Sefton, St Helens and Wirral with a total
population of 1 506 935 of predominantly white, British
or Irish heritage (93.2%). Approximately 8000 babies
are delivered annually at the LWH.
Enrolment and follow-up of mother–infant pairs
Pregnant women in their third trimester available for
follow-up for at least 4 months postnatally will be
informed about the study by the visiting ﬁeld staff or by
post and be invited to participate in the study. Women
with a prior diagnosis of congenital immune deﬁciency,
chronic renal or liver failure, other chronic illnesses
which might affect immune response (other than HIV)
and mothers with non-singleton pregnancy will be
excluded. Following the initial screening, women who
subsequently deliver preterm babies (<34 weeks of gesta-
tion) will be excluded. After screening and informed
consent is obtained, body mass index, haemoglobin and
HIV status will be documented. A blood sample of 5 mL
will be collected from the mother by the phlebotomist
for baseline anti-RV IgG and IgA levels. Following deliv-
ery, mode and place of delivery, gender and birth weight
will be documented by the staff conducting the delivery;
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sample collection, as outlined in ﬁgure 2, will be con-
ducted by the ﬁeld staff/phlebotomist/study nurse as
per the calendar generated immediately following the
delivery of the infant. The mother–infant pair will be
followed until the infant completes the third dose of
routine immunisation, which marks the end of the study.
Except the birth dose of BCG, Hepatitis B and OPV
(India) which are usually administered at the point of
delivery, all routine immunisations along with two doses
of RV vaccine (Rotarix) will be administered to the
infants as per the site’s national immunisation schedule
(table 1). History of prelacteal feeds and initiation of
breast feeding details will be collected. At every sampling
point, details of breast feeding, prior and current illness
if any and antibiotic usage will be documented. The
levels of prevaccination maternally derived RV-speciﬁc
antibodies (IgG) will be correlated with infant serocon-
version and antibody titres (immunogenicity) 4 weeks
after two doses of RV vaccine are administered.
Sample size
Approximately 40% of the Indian and African infants
are expected to seroconvert following two doses of RV
vaccine.33–35 A sample size of 150 infants would thereby
give a power of 80% to detect a twofold higher mean
concentration of RV-speciﬁc IgG antibodies at 6 weeks in
those who fail to seroconvert compared with those who
seroconvert, assuming an SE of 1 loge International
Unit, and 90% power to detect a correlation between
the concentration of RV-speciﬁc serum IgA at 6 and
14 weeks.7 In the UK, 95% of infants are expected to
seroconvert. The levels of RV-speciﬁc serum IgA anti-
body titres of infants in the UK will be compared with
those in India and Malawi. Hence, a sample size of 50 in
the UK would give a power of 79% to compare antibody
concentrations according to seroconversion status across
the study sites with a 10% allowance for potential loss to
follow-up, giving a sample size 165 mother–infant pairs
in India and Malawi, and 55 mother–infant pairs in the
UK.
The sample size calculated is also powered to >95% to
detect a signiﬁcant difference in the (Shannon) diversity
of the gut microbiota at the time of vaccination between
infants who seroconvert and those who do not, both
within the infants at India and Malawi and in compari-
son with those at the UK, based on in-house observa-
tions of this variance in 6-week-old infants (unpublished
data) and a difference of 0.5 consistent with that
observed during episodes of malnutrition or diar-
rhoea.23 It is expected that ∼21 and 8 infants would get
infected or develop RV diarrhoea, respectively, before
the 6th week immunisation visit in Vellore, and similarly
in Malawi (data not available for UK).11 33 Maternally
derived antibody and microbiota will be compared in
the infants who had RV diarrhoea with the other infants
in the study, but substantial power in these analyses may
not be possible.
To determine the potential interference of OPV coad-
ministration with RV vaccine apropos to the differences
in immunogenicity between the UK and Indian infants
(where bivalent OPV continues to be a part of the
national immunisation schedule), OPV will be replaced
Figure 2 Schematic representation of enrolment and follow-up of the mother–infant pairs at Malawi, India and UK.
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with IPV for an additional cohort of 90 infants recruited
in India that is powered to 83% to detect a 20% differ-
ence in seroconversion following two doses of RV
vaccine, assuming a 10% loss to follow-up.36
Outcome measures
The levels of prevaccination maternally derived RV-
speciﬁc antibodies (IgG) will be correlated with infant
seroconversion and antibody titres (immunogenicity)
4 weeks after two doses of RV vaccine are administered
at 6th and 10th week of age (WHO-recommended
schedule applied in India and Malawi) or 8th and 12th
week of age (UK national recommendation) (table 1).
In addition, RV shedding in stool on day 7 following
each vaccine dose will be tested as an additional marker
of vaccine take (ﬁgure 2).
Comparison of gut microbial communities will be per-
formed among infants who seroconvert with those who
do not, both within and between populations, in order
to determine whether infants who fail to seroconvert fol-
lowing RV vaccination have a distinct microbiota.
The impact of OPV coadministration on RV vaccine
response in India will be studied by including an add-
itional arm where OPV will be replaced by IPV at 6th
and 10th week (following OPV at birth), to allow com-
parisons with Indian children coadministered OPV and
with children in the UK who receive IPV. This will
provide data that may enable prediction of the perform-
ance of RV vaccines when IPV is introduced in develop-
ing countries later, especially since a single dose of IPV
in immunisation schedules of six states from November
2016 in India.37 38
Laboratory methods
Specimen processing and storage
All specimens will be transported to the receiving labora-
tory at each site within 24 hours of collection. Blood
samples will be separated for plasma and be frozen until
further testing. Stool and breast milk specimens will be
stored frozen at −70°C.
Immunology
RV-speciﬁc IgG or IgA antibodies will be detected using
standardised quantitative ELISA methods that have been
validated and are certiﬁed for regulatory submissions for
RV vaccine trials. Levels of RV-speciﬁc IgG and IgA will
be measured in the mother’s blood, cord blood and
infant’s blood specimens to allow for the assessment of
transplacentally acquired antibodies and possibly the dur-
ation of maternally transferred protection in the infant
(IgG) at the following time points: early exposure (birth
to the ﬁrst dose of RV vaccine), prior to RV vaccine
immunisation, potential RV infections (infant IgA prior
to vaccine dose) and seroconversion post-RV immunisa-
tion (infant IgA at 14th or 16th week) (table 2).
Innate immunity activation markers of enteric infec-
tion that could potentially affect the immune response
to RV vaccine will be assessed in a subset of samples
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from Malawi and India where blood (1 mL) will be col-
lected in a TruCulture whole blood culture tube with
and without stimulant (0.5 mL in each), incubated and
frozen for analysis of cytokine expression.39 Poly I:C
(stimulant), which interacts with toll-like receptor 3,
expressed in the membrane of B-cells, macrophages and
dendritic cells, a synthetic analogue of dsRNA, which in
turn is a molecular pattern associated with viral infection
will enable the study of patterns of innate immune
responses triggered by viral infections between children
who seroconvert and those who do not following RV
immunisation (table 2).
Virology
RV and poliovirus vaccine strains (1 and 3) will be
detected in stool samples using previously validated Real
Time/quantitative PCR assays (qPCR). A 10–20% stool
suspension will be prepared in phosphate buffer solu-
tion prior to total nucleic acid extraction. The extracted
nucleic acid will be used to generate cDNA by reverse
transcription using random hexamers and this will serve
as a template in the RV and OPV qPCRs.
RV vaccine take will be determined through detection
of RV vaccine strain shedding in stool 1 week postvacci-
nation, using Rotarix-speciﬁc qPCR. OPV shedding will
be measured by detecting Sabin poliovirus types 1 and 3
shedding in stool, 1 week postvaccination, also by qPCR
(table 2).
Markers of local (gut) inflammation
This will be assessed using commercially available ELISA
for the detection of AAT and MPO in stool samples.
Systemic inﬂammation will be assessed using a
commercially available ELISA for the detection of acid
glycoprotein in serum/plasma. These assays will be per-
formed in each of the three laboratories using the same
methods and the same batch of kits (table 2).
Microbiota
Samples for microbiota analysis will be stored for a
maximum of 2 weeks prior to DNA extraction. Nucleic
acid extraction will be carried out at each of the sites.
Samples will be treated by bead beating and lysozyme
prior to DNA extraction with the QiagenQIAamp DNA
stool extraction kit (table 2). Blank water controls will
be included in each extraction batch and run through
as sequencing controls. Extracted DNA will be aliquoted
and stored at −20°C prior to ampliﬁcation. All sites will
adopt the same SOPs to ensure that sample collection
and DNA extraction and sequencing are standardised
and that the data are comparable between sites.
All frozen DNA samples will be shipped to Liverpool,
UK, undergo quality control and library construction
using a Nextera v2 Dual Index Barcoding approach,
before sequencing on the IIlumina HiSeq 2500 Rapid
Run mode or alternatively the Illumina MiSeq platform.
Approximately 10% of the samples will additionally be
sequenced at Imperial College London to test the repro-
ducibility and robustness of the protocols and allow com-
parison and validation.
The 16S rDNA PCR strategy will use a nested dual
index protocol to amplify and barcode the variable V3–
V4 region (319f—5′ ACTCCTACGGGAGGCAGCAG 3′ &
806r—5′ GGACTACHVGGGTWTCTAAT 3′) resulting in
∼469 base pair PCR product. Then barcoded 16s PCR
products will be multiplexed and sequenced on the
Table 2 Summary of the laboratory tests and assays
Domain Laboratory parameter
Type of
specimen Method/assay
Immunology Rotavirus (RV)-specific IgG antibodies ▸ Mother’s blood
▸ Cord blood
▸ Infant’s blood
ELISA
RV-specific IgA antibodies
Innate immunity activation markers Infant’s blood TruCulture blood collection
and whole-blood culture
systems
Virology Rotavirus shedding ▸ Mother’s stool
▸ Infant’s stool
qPCR
Poliovirus shedding (type 1 and 3) ▸ Mother’s stool
▸ Infant’s stool
qPCR
Markers of
inflammation
Local (gut) inflammation ▸ α-1-Antitrypsin (ATT)
▸ Myeloperoxidase
Infant’s stool ELISA
Systemic inflammation Acid glycoprotein Infant’s blood ELISA
Microbiota Characterisation of microbiota composition ▸ Mother’s stool
▸ Breast milk
▸ Infant’s stool
DNA extraction
Amplification
Next generation
Sequencing
qPCR, quantitative PCR.
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Illumina HiSeq 2500 or MiSeq platform to produce
2×250 base pair reads.
Statistical analysis
Role of pre-existing IgG and RV exposure
The mean log-concentration of RV-speciﬁc antibody
(IgG, IgA) measured at 6 weeks in infants who serocon-
vert or not following RV vaccination will be compared
using Student’s t-test or a non-parametric test as appro-
priate. The associations between seroconversion and
maternal factors, including infection status and early
infant exposure to RV infection, will be assessed using
Student’s t-test or χ2 test as appropriate and multivariate
logistic regression will be performed to deduce interac-
tions between these variables. Similar analyses will be
performed for infants grouped according to the detec-
tion of RV shedding in the week following vaccination as
a marker of vaccine take.
Microbiota
V3/V4 sequences will undergo a validated error correc-
tion protocol. Quality ﬁltering, including the trimming
of low-quality bases at the start and end of each read
with Sickle (https://github.com/najoshi/sickle) and
error correction using Bayes Hammer, will be performed
prior to the assembly of paired reads with PEAR
(V.0.9.1) or equivalent.40 41 A size selection ﬁlter set to
the expected amplicon size and BLAST searches ensure
that PhiX spike in control is detected and removed.
These corrected and assembled reads will then be ana-
lysed with QIIME (Quantitative Insights Into Microbial
Ecology).42 USEARCH will be run using de novo and
open reference operational taxonomic units (OTU)
clustering methods, and de novo chimera detection con-
ducted with UCHIME V.5.1.43 44 Taxonomy will be
assigned to OTUs using the naïve Bayesian RDP
(Ribosomal Database Project) Classiﬁer using the SILVA
and GREENGENES taxonomic databases.
Estimates of within-sample species richness (number
of OTUs) and diversity (Shannon index) at multiple
rarefaction depths will be compared between infants
who seroconvert and those who fail to seroconvert
using Student’s t-test. Weighted and unweighted
UniFrac distances will be used to assess potential clus-
tering of microbiota composition according to serocon-
version status, as well as the degree of overlap in
composition according to the age and geographical
location. These results will be visualised using principal
coordinates analyses and statistically signiﬁcant clusters
will be identiﬁed using Adonis. Random forests will be
used to identify OTUs that distinguish individuals
according to RV vaccine response, age and geograph-
ical location.
Effect of OPV coadministration on RV immunogenicity
The effect of administration of OPV on RV vaccine
immunogenicity will be assessed by comparing serocon-
version and geometric mean concentrations (GMC of R
IgA) between infants in India in the OPV and IPV
cohorts using the χ2 test and Student’s t-test (or non-
parametric equivalent), respectively.
DISCUSSION
Maternal antibodies to RV are higher in low-income
countries and in both in trials of withholding breast
feeding in India and elsewhere and animal models have
demonstrated that maternal antibodies interfere to
some extent with RV vaccine immune response.14 45 46
However, their comparative effect on the immunogen-
icity of RV vaccination among populations of the devel-
oping and developed world is currently unknown.
Additionally, the relationship between systemic anti-
bodies and secretory antibodies in breast milk is not
known; although the studies of withholding breast
feeding immediately prior to RV immunisation did not
signiﬁcantly impact the vaccine immunogenicity.46 47
Levels of transplacental transfer of IgG to the infant may
be inﬂuenced by risk factors such as the high prevalence
of HIV in resource-poor settings irrespective of the high
maternal RV-speciﬁc antibody levels from reinfections,
such as may be understood from Malawi, with a mater-
nal HIV prevalence of 20%.48 Despite efforts to study
the interactions between commensal bacteria and host
immune responses, the role of the intestinal microbiota
on vaccine response remains underinvestigated, espe-
cially in heterogeneous populations. Evaluation of
immunogenicity of oral RV vaccines given with OPV and
potential for interference have been described from
Bangladesh, but not with vaccination on a routine
immunisation schedule.49 This study will evaluate per-
formance of the RV vaccine in the routine schedule in
two developing counties where OPV may be soon
phased out to be replaced with IPV as per the Global
Polio Eradication Initiative (GPEI) Strategic Plan for
2013–2018.
This study will provide information on multiple factors
that may help to understand the performance of RV vac-
cines and thus develop strategies for improvement, espe-
cially where the vaccines are less effective in reducing
the burden of RV gastroenteritis.
DISSEMINATION
Participant recruitment began in 2016 and follow-up of
the mother–infant pairs is ongoing at all three sites.
Analysis of data, followed by publication of the results, is
expected in 2018.
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